{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:13:43Z","timestamp":1794366823956,"version":"4.9.0"},"reference-count":332,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41573-022-00495-3","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T08:05:02Z","timestamp":1655712302000},"page":"676-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":294,"title":["Antibodies to combat viral infections: development strategies and progress"],"prefix":"10.1038","volume":"21","author":[{"given":"Giuseppe","family":"Pantaleo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S.","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-7928","authenticated-orcid":false,"given":"Laurent","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"495_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495\u2013497 (1975).","journal-title":"Nature"},{"key":"495_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 20, 491\u2013495 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"495_CR3","first-page":"1113","volume":"49","author":"EV Behring","year":"1890","unstructured":"Behring, E. V. & Kitasato, S. \u00dcber das Zustandekommen der Diphtherie-Immunit\u00e4t und der Tetanus-Immunit\u00e4t bei Thieren. Dtsch Med. Wochenschrift 49, 1113\u20131114 (1890).","journal-title":"Dtsch Med. Wochenschrift"},{"key":"495_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/QCO.0000000000000539","volume":"32","author":"MP Motley","year":"2019","unstructured":"Motley, M. P., Banerjee, K. & Fries, B. C. Monoclonal antibody-based therapies for bacterial infections. Curr. Opin. Infect. Dis. 32, 210\u2013216 (2019).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"495_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.tim.2018.12.009","volume":"27","author":"D Raafat","year":"2019","unstructured":"Raafat, D., Otto, M., Reppschl\u00e4ger, K., Iqbal, J. & Holtfreter, S. Fighting Staphylococcus aureus biofilms with monoclonal antibodies. Trends Microbiol. 27, 303\u2013322 (2019).","journal-title":"Trends Microbiol."},{"key":"495_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/2049-632X.12034","volume":"67","author":"A Hjelholt","year":"2013","unstructured":"Hjelholt, A., Christiansen, G., S\u00f8rensen, U. S. & Birkelund, S. IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens. Pathog. Dis. 67, 206\u2013213 (2013).","journal-title":"Pathog. Dis."},{"key":"495_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","volume":"588","author":"S Bournazos","year":"2020","unstructured":"Bournazos, S., Corti, D., Virgin, H. W. & Ravetch, J. V. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature 588, 485\u2013490 (2020).","journal-title":"Nature"},{"key":"495_CR8","doi-asserted-by":"publisher","first-page":"17965","DOI":"10.1073\/pnas.1415310111","volume":"111","author":"A Kabanova","year":"2014","unstructured":"Kabanova, A. et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc. Natl Acad. Sci. USA 111, 17965\u201317970 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR9","doi-asserted-by":"publisher","first-page":"26933","DOI":"10.1073\/pnas.1916028116","volume":"116","author":"Q Zheng","year":"2019","unstructured":"Zheng, Q. et al. Viral neutralization by antibody-imposed physical disruption. Proc. Natl Acad. Sci. USA 116, 26933\u201326940 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR10","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20209610","volume":"16","author":"F Hikmet","year":"2020","unstructured":"Hikmet, F. et al. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16, e9610 (2020).","journal-title":"Mol. Syst. Biol."},{"key":"495_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382\u2013393 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"495_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46\u201361 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"495_CR13","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","volume":"184","author":"ES Winkler","year":"2021","unstructured":"Winkler, E. S. et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell 184, 1804\u20131820.e16 (2021).","journal-title":"Cell"},{"key":"495_CR14","doi-asserted-by":"publisher","unstructured":"Sch\u00e4fer, A. et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20201993 (2021).","DOI":"10.1084\/jem.20201993"},{"key":"495_CR15","doi-asserted-by":"publisher","unstructured":"Case, J. B. et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.03.17.484787 (2022).","DOI":"10.1101\/2022.03.17.484787"},{"key":"495_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","volume":"20","author":"S Bournazos","year":"2020","unstructured":"Bournazos, S., Gupta, A. & Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat. Rev. Immunol. 20, 633\u2013643 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"495_CR17","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3201\/eid0812.020170","volume":"8","author":"SB Halstead","year":"2002","unstructured":"Halstead, S. B. et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8, 1474\u20131479 (2002).","journal-title":"Emerg. Infect. Dis."},{"key":"495_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","volume":"328","author":"W Dejnirattisai","year":"2010","unstructured":"Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745\u2013748 (2010).","journal-title":"Science"},{"key":"495_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","volume":"8","author":"M Beltramello","year":"2010","unstructured":"Beltramello, M. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271\u2013283 (2010).","journal-title":"Cell Host Microbe"},{"key":"495_CR20","doi-asserted-by":"crossref","unstructured":"Xu, L., Ma, Z., Li, Y., Pang, Z. & Xiao, S. in Advances in Immunology Vol. 151 (eds Frederick W. A. & Kenneth M. M.) 99\u2013133 (Academic, 2021).","DOI":"10.1016\/bs.ai.2021.08.003"},{"key":"495_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"J Mair-Jenkins","year":"2015","unstructured":"Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80\u201390 (2015).","journal-title":"J. Infect. Dis."},{"key":"495_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/nrmicro974","volume":"2","author":"A Casadevall","year":"2004","unstructured":"Casadevall, A., Dadachova, E. & Pirofski, L.-A. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2, 695\u2013703 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"495_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/ACI.0000000000000787","volume":"21","author":"L Hammarstr\u00f6m","year":"2021","unstructured":"Hammarstr\u00f6m, L., Marcotte, H., Piralla, A., Baldanti, F. & Pan-Hammarstr\u00f6m, Q. Antibody therapy for COVID-19. Curr. Opin. Allergy Clin. Immunol. 21, 553\u2013558 (2021).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"495_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"VA Simonovich","year":"2021","unstructured":"Simonovich, V. A. et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N. Engl. J. Med. 384, 619\u2013629 (2021).","journal-title":"N. Engl. J. Med."},{"key":"495_CR25","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","volume":"27","author":"P B\u00e9gin","year":"2021","unstructured":"B\u00e9gin, P. et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat. Med. 27, 2012\u20132024 (2021).","journal-title":"Nat. Med."},{"key":"495_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28064-7","volume":"13","author":"Y Ray","year":"2022","unstructured":"Ray, Y. et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Nat. Commun. 13, 383 (2022).","journal-title":"Nat. Commun."},{"key":"495_CR27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/348552a0","volume":"348","author":"J McCafferty","year":"1990","unstructured":"McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552\u2013554 (1990).","journal-title":"Nature"},{"key":"495_CR28","first-page":"1","volume":"178","author":"HR Hoogenboom","year":"2002","unstructured":"Hoogenboom, H. R. Overview of antibody phage-display technology and its applications. Methods Mol. Biol. 178, 1\u201337 (2002).","journal-title":"Methods Mol. Biol."},{"key":"495_CR29","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1126\/science.7973652","volume":"266","author":"DR Burton","year":"1994","unstructured":"Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024\u20131027 (1994).","journal-title":"Science"},{"key":"495_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27799-z","volume":"13","author":"F Ferrara","year":"2022","unstructured":"Ferrara, F. et al. A pandemic-enabled comparison of discovery platforms demonstrates a na\u00efve antibody library can match the best immune-sourced antibodies. Nat. Commun. 13, 462 (2022).","journal-title":"Nat. Commun."},{"key":"495_CR31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nbt0602-597","volume":"20","author":"JA Maynard","year":"2002","unstructured":"Maynard, J. A. et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20, 597\u2013601 (2002).","journal-title":"Nat. Biotechnol."},{"key":"495_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/19420862.2015.1123365","volume":"8","author":"A Burkovitz","year":"2016","unstructured":"Burkovitz, A. & Ofran, Y. Understanding differences between synthetic and natural antibodies can help improve antibody engineering. mAbs 8, 278\u2013287 (2016).","journal-title":"mAbs"},{"key":"495_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/intimm\/dxh214","volume":"17","author":"T Novobrantseva","year":"2005","unstructured":"Novobrantseva, T. et al. Stochastic pairing of Ig heavy and light chains frequently generates B cell antigen receptors that are subject to editing in vivo. Int. Immunol. 17, 343\u2013350 (2005).","journal-title":"Int. Immunol."},{"key":"495_CR34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1084\/jem.177.4.1009","volume":"177","author":"SL Tiegs","year":"1993","unstructured":"Tiegs, S. L., Russell, D. M. & Nemazee, D. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177, 1009\u20131020 (1993).","journal-title":"J. Exp. Med."},{"key":"495_CR35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1084\/jem.177.4.999","volume":"177","author":"D Gay","year":"1993","unstructured":"Gay, D., Saunders, T., Camper, S. & Weigert, M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177, 999\u20131008 (1993).","journal-title":"J. Exp. Med."},{"key":"495_CR36","first-page":"886","volume":"20","author":"MH Norris","year":"2020","unstructured":"Norris, M. H. & Blackburn, J. K. Raxibacumab: a panacea for anthrax disease? Lancet Infect. Dis. 20, 886\u2013887 (2020).","journal-title":"Infect. Dis."},{"key":"495_CR37","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.it.2021.10.008","volume":"42","author":"A Pedrioli","year":"2021","unstructured":"Pedrioli, A. & Oxenius, A. Single B cell technologies for monoclonal antibody discovery. Trends Immunol. 42, 1143\u20131158 (2021).","journal-title":"Trends Immunol."},{"key":"495_CR38","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1084\/jem.180.4.1383","volume":"180","author":"U Klein","year":"1994","unstructured":"Klein, U., K\u00fcppers, R. & Rajewsky, K. Variable region gene analysis of B cell subsets derived from a 4-year-old child: somatically mutated memory B cells accumulate in the peripheral blood already at young age. J. Exp. Med. 180, 1383\u20131393 (1994).","journal-title":"J. Exp. Med."},{"key":"495_CR39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nbt.2825","volume":"32","author":"EC Lee","year":"2014","unstructured":"Lee, E. C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356\u2013363 (2014).","journal-title":"Nat. Biotechnol."},{"key":"495_CR40","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nature07930","volume":"458","author":"JF Scheid","year":"2009","unstructured":"Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636\u2013640 (2009).","journal-title":"Nature"},{"key":"495_CR41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"495_CR42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11544","volume":"491","author":"J Huang","year":"2012","unstructured":"Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406\u2013412 (2012).","journal-title":"Nature"},{"key":"495_CR43","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/nsmb.2594","volume":"20","author":"L Kong","year":"2013","unstructured":"Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796\u2013803 (2013).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"495_CR44","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1128\/JVI.73.5.4009-4018.1999","volume":"73","author":"JR Mascola","year":"1999","unstructured":"Mascola, J. R. et al. Protection of macaques against pathogenic simian\/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009\u20134018 (1999).","journal-title":"J. Virol."},{"key":"495_CR45","doi-asserted-by":"publisher","first-page":"18921","DOI":"10.1073\/pnas.1214785109","volume":"109","author":"B Moldt","year":"2012","unstructured":"Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921\u201318925 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.chom.2020.05.010","volume":"28","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations. Cell Host Microbe 28, 335\u2013349.e6 (2020).","journal-title":"Cell Host Microbe"},{"key":"495_CR47","doi-asserted-by":"publisher","first-page":"eabf8891","DOI":"10.1126\/sciimmunol.abf8891","volume":"5","author":"GE Hartley","year":"2020","unstructured":"Hartley, G. E. et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci. Immunol. 5, eabf8891 (2020).","journal-title":"Sci. Immunol."},{"key":"495_CR48","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1128\/JVI.01809-09","volume":"84","author":"A Macagno","year":"2010","unstructured":"Macagno, A. et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex. J. Virol. 84, 1005\u20131013 (2010).","journal-title":"J. Virol."},{"key":"495_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12484","volume":"275","author":"LE McCoy","year":"2017","unstructured":"McCoy, L. E. & Burton, D. R. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol. Rev. 275, 11\u201320 (2017).","journal-title":"Immunol. Rev."},{"key":"495_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nm.2071","volume":"16","author":"MJ Kwakkenbos","year":"2010","unstructured":"Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123\u2013128 (2010).","journal-title":"Nat. Med."},{"key":"495_CR51","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm1080","volume":"10","author":"E Traggiai","year":"2004","unstructured":"Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10, 871\u2013875 (2004).","journal-title":"Nat. Med."},{"key":"495_CR52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/269420a0","volume":"269","author":"M Steinitz","year":"1977","unstructured":"Steinitz, M., Klein, G., Koskimies, S. & Makel, O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269, 420\u2013422 (1977).","journal-title":"Nature"},{"key":"495_CR53","doi-asserted-by":"publisher","unstructured":"Corti, D. & Lanzavecchia, A. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Microbiol. Spectr. https:\/\/doi.org\/10.1128\/microbiolspec.AID-0018-2014 (2014).","DOI":"10.1128\/microbiolspec.AID-0018-2014"},{"key":"495_CR54","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2016.02.010","volume":"44","author":"M Kuraoka","year":"2016","unstructured":"Kuraoka, M. et al. Complex antigens drive permissive clonal selection in germinal centers. Immunity 44, 542\u2013552 (2016).","journal-title":"Immunity"},{"key":"495_CR55","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.4049\/jimmunol.1502193","volume":"197","author":"K-Y Su","year":"2016","unstructured":"Su, K.-Y., Watanabe, A., Yeh, C.-H., Kelsoe, G. & Kuraoka, M. Efficient culture of human naive and memory B cells for use as APCs. J. Immunol. 197, 4163\u20134176 (2016).","journal-title":"J. Immunol."},{"key":"495_CR56","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2008-09-177139","volume":"113","author":"XM Luo","year":"2009","unstructured":"Luo, X. M. et al. Engineering human hematopoietic stem\/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113, 1422\u20131431 (2009).","journal-title":"Blood"},{"key":"495_CR57","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.immuni.2017.12.009","volume":"48","author":"KR McCarthy","year":"2018","unstructured":"McCarthy, K. R. et al. Memory B cells that cross-react with group 1 and group 2 influenza A viruses are abundant in adult human repertoires. Immunity 48, 174\u2013184.e9 (2018).","journal-title":"Immunity"},{"key":"495_CR58","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.immuni.2019.02.003","volume":"50","author":"JM Lindner","year":"2019","unstructured":"Lindner, J. M. et al. Human memory B cells harbor diverse cross-neutralizing antibodies against BK and JC polyomaviruses. Immunity 50, 668\u2013676.e5 (2019).","journal-title":"Immunity"},{"key":"495_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-020-01145-0","volume":"27","author":"LE Wagar","year":"2021","unstructured":"Wagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125\u2013135 (2021).","journal-title":"Nat. Med."},{"key":"495_CR60","doi-asserted-by":"publisher","first-page":"eaay9093","DOI":"10.1126\/sciadv.aay9093","volume":"6","author":"H Tanno","year":"2020","unstructured":"Tanno, H. et al. A facile technology for the high-throughput sequencing of the paired VH:VL and TCR\u03b2:TCR\u03b1 repertoires. Sci. Adv. 6, eaay9093 (2020).","journal-title":"Sci. Adv."},{"key":"495_CR61","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/nm.3743","volume":"21","author":"BJ DeKosky","year":"2015","unstructured":"DeKosky, B. J. et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat. Med. 21, 86\u201391 (2015).","journal-title":"Nat. Med."},{"key":"495_CR62","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41590-021-00936-y","volume":"22","author":"D Chen","year":"2021","unstructured":"Chen, D. et al. Coupled analysis of transcriptome and BCR mutations reveals role of OXPHOS in affinity maturation. Nat. Immunol. 22, 904\u2013913 (2021).","journal-title":"Nat. Immunol."},{"key":"495_CR63","doi-asserted-by":"publisher","first-page":"108863","DOI":"10.1016\/j.celrep.2021.108863","volume":"34","author":"EA Thompson","year":"2021","unstructured":"Thompson, E. A. et al. Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Rep. 34, 108863 (2021).","journal-title":"Cell Rep."},{"key":"495_CR64","doi-asserted-by":"publisher","unstructured":"Buus, T. B. et al. Improving oligo-conjugated antibody signal in multimodal single-cell analysis. eLife https:\/\/doi.org\/10.7554\/eLife.61973 (2021).","DOI":"10.7554\/eLife.61973"},{"key":"495_CR65","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2021.04.003","volume":"54","author":"A Ramaswamy","year":"2021","unstructured":"Ramaswamy, A. et al. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity 54, 1083\u20131095.e7 (2021).","journal-title":"Immunity"},{"key":"495_CR66","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cbpa.2014.11.007","volume":"24","author":"JJ Lavinder","year":"2015","unstructured":"Lavinder, J. J., Horton, A. P., Georgiou, G. & Ippolito, G. C. Next-generation sequencing and protein mass spectrometry for the comprehensive analysis of human cellular and serum antibody repertoires. Curr. Opin. Chem. Biol. 24, 112\u2013120 (2015).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"495_CR67","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nbt.2782","volume":"32","author":"G Georgiou","year":"2014","unstructured":"Georgiou, G. et al. The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat. Biotechnol. 32, 158\u2013168 (2014).","journal-title":"Nat. Biotechnol."},{"key":"495_CR68","unstructured":"Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment during Outbreaks: Interim Guidance for National Health Authorities and Blood Transfusion Services Version 1.0 (World Health Organization, 2014)."},{"key":"495_CR69","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.cell.2019.11.003","volume":"179","author":"I Setliff","year":"2019","unstructured":"Setliff, I. et al. High-throughput mapping of B cell receptor sequences to antigen specificity. Cell 179, 1636\u20131646.e15 (2019).","journal-title":"Cell"},{"key":"495_CR70","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.str.2020.07.012","volume":"28","author":"JA Finn","year":"2020","unstructured":"Finn, J. A. et al. Identification of structurally related antibodies in antibody sequence databases using rosetta-derived position-specific scoring. Structure 28, 1124\u20131130.e5 (2020).","journal-title":"Structure"},{"key":"495_CR71","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.str.2020.04.005","volume":"28","author":"AM Sevy","year":"2020","unstructured":"Sevy, A. M. et al. Computationally designed cyclic peptides derived from an antibody loop increase breadth of binding for influenza variants. Structure 28, 1114\u20131123.e4 (2020).","journal-title":"Structure"},{"key":"495_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007731","volume":"16","author":"M Foglierini","year":"2020","unstructured":"Foglierini, M., Pappas, L., Lanzavecchia, A., Corti, D. & Perez, L. AncesTree: an interactive immunoglobulin lineage tree visualizer. PLoS Comput. Biol. 16, e1007731 (2020).","journal-title":"PLoS Comput. Biol."},{"key":"495_CR73","doi-asserted-by":"publisher","first-page":"109784","DOI":"10.1016\/j.celrep.2021.109784","volume":"37","author":"KJ Kramer","year":"2021","unstructured":"Kramer, K. J. et al. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Rep. 37, 109784 (2021).","journal-title":"Cell Rep."},{"key":"495_CR74","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.4049\/jimmunol.147.8.2657","volume":"147","author":"J Lund","year":"1991","unstructured":"Lund, J. et al. Human Fc\u03b3RI and Fc\u03b3RII interact with distinct but overlapping sites on human IgG. J. Immunol. 147, 2657\u20132662 (1991).","journal-title":"J. Immunol."},{"key":"495_CR75","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 5, 1185\u20131191 (2020).","journal-title":"Nat. Microbiol."},{"key":"495_CR76","doi-asserted-by":"publisher","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","volume":"14","author":"Y-M Loo","year":"2022","unstructured":"Loo, Y.-M. et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci. Transl Med. 14, eabl8124 (2022).","journal-title":"Sci. Transl Med."},{"key":"495_CR77","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1107\/S0907444908007877","volume":"64","author":"V Oganesyan","year":"2008","unstructured":"Oganesyan, V., Gao, C., Shirinian, L., Wu, H. & Dall\u2019Acqua, W. F. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. Sect. D. 64, 700\u2013704 (2008).","journal-title":"Acta Crystallogr. Sect. D."},{"key":"495_CR78","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941\u20131950 (2021).","journal-title":"N. Engl. J. Med."},{"key":"495_CR79","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1172\/JCI128437","volume":"129","author":"P Weitzenfeld","year":"2019","unstructured":"Weitzenfeld, P., Bournazos, S. & Ravetch, J. V. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. J. Clin. Invest. 129, 3952\u20133962 (2019).","journal-title":"J. Clin. Invest."},{"key":"495_CR80","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.coviro.2019.07.007","volume":"38","author":"M Grobben","year":"2019","unstructured":"Grobben, M., Stuart, R. A. & van Gils, M. J. The potential of engineered antibodies for HIV-1 therapy and cure. Curr. Opin. Virol. 38, 70\u201380 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"495_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002493","volume":"15","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).","journal-title":"PLoS Med."},{"key":"495_CR82","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","volume":"88","author":"RS Rudicell","year":"2014","unstructured":"Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669\u201312682 (2014).","journal-title":"J. Virol."},{"key":"495_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003342","volume":"9","author":"J-P Julien","year":"2013","unstructured":"Julien, J.-P. et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 9, e1003342 (2013).","journal-title":"PLoS Pathog."},{"key":"495_CR84","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u2019Acqua","year":"2006","unstructured":"Dall\u2019Acqua, W. F., Kiener, P. A. & Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514\u201323524 (2006).","journal-title":"J. Biol. Chem."},{"key":"495_CR85","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin, M. P. et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N. Engl. J. Med. 383, 415\u2013425 (2020).","journal-title":"N. Engl. J. Med."},{"key":"495_CR86","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt, L. L. et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 386, 837\u2013846 (2022).","journal-title":"N. Engl. J. Med."},{"key":"495_CR87","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/INF.0000000000001916","volume":"37","author":"JB Domachowske","year":"2018","unstructured":"Domachowske, J. B. et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr. Infect. Dis. J. 37, 886\u2013892 (2018).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"495_CR88","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"495_CR89","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1126\/science.aag3267","volume":"354","author":"AZ Wec","year":"2016","unstructured":"Wec, A. Z. et al. A \u201cTrojan horse\u201d bispecific-antibody strategy for broad protection against ebolaviruses. Science 354, 350\u2013354 (2016).","journal-title":"Science"},{"key":"495_CR90","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.cell.2016.04.050","volume":"165","author":"S Bournazos","year":"2016","unstructured":"Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C. & Ravetch, J. V. Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165, 1609\u20131620 (2016).","journal-title":"Cell"},{"key":"495_CR91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aan8630","volume":"358","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358, 85\u201390 (2017).","journal-title":"Science"},{"key":"495_CR92","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"495_CR93","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 380, 335\u2013346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"495_CR94","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41586-021-03676-z","volume":"595","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature 595, 278\u2013282 (2021).","journal-title":"Nature"},{"key":"495_CR95","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pl\u00fcckthun","year":"2015","unstructured":"Pl\u00fcckthun, A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55, 489\u2013511 (2015).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"495_CR96","doi-asserted-by":"publisher","unstructured":"Rothenberger, S. et al. Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2021.02.03.429164 (2022).","DOI":"10.1101\/2021.02.03.429164"},{"key":"495_CR97","doi-asserted-by":"publisher","unstructured":"Walser, M. et al. Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.08.25.256339 (2021).","DOI":"10.1101\/2020.08.25.256339"},{"key":"495_CR98","doi-asserted-by":"crossref","unstructured":"DARPins stack up as anti-COVID-19 agents. Nat. Biotechnol. 38, 1369\u20131369 (2020).","DOI":"10.1038\/s41587-020-00771-w"},{"key":"495_CR99","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","volume":"24","author":"S Su","year":"2016","unstructured":"Su, S. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 24, 490\u2013502 (2016).","journal-title":"Trends Microbiol."},{"key":"495_CR100","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155\u2013170 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"495_CR101","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jcv.2018.01.019","volume":"101","author":"ME Killerby","year":"2018","unstructured":"Killerby, M. E. et al. Human coronavirus circulation in the United States 2014\u20132017. J. Clin. Virol. 101, 52\u201356 (2018).","journal-title":"J. Clin. Virol."},{"key":"495_CR102","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa031349","volume":"349","author":"SJ Olsen","year":"2003","unstructured":"Olsen, S. J. et al. Transmission of the severe acute respiratory syndrome on aircraft. N. Engl. J. Med. 349, 2416\u20132422 (2003).","journal-title":"N. Engl. J. Med."},{"key":"495_CR103","doi-asserted-by":"publisher","first-page":"12995","DOI":"10.1073\/pnas.1735582100","volume":"100","author":"B Yount","year":"2003","unstructured":"Yount, B. et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 100, 12995\u201313000 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR104","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S1473-3099(13)70304-9","volume":"14","author":"S Cauchemez","year":"2014","unstructured":"Cauchemez, S. et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect. Dis. 14, 50\u201356 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"495_CR105","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nrmicro3143","volume":"11","author":"RL Graham","year":"2013","unstructured":"Graham, R. L., Donaldson, E. F. & Baric, R. S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11, 836\u2013848 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"495_CR106","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"495_CR107","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514\u2013523 (2020).","journal-title":"Lancet"},{"key":"495_CR108","unstructured":"Coronavirus disease (COVID-19) pandemic. World Health Organization https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (2021)."},{"key":"495_CR109","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","volume":"495","author":"VS Raj","year":"2013","unstructured":"Raj, V. S. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251\u2013254 (2013).","journal-title":"Nature"},{"key":"495_CR110","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","volume":"479-480","author":"SC Harrison","year":"2015","unstructured":"Harrison, S. C. Viral membrane fusion. Virology 479-480, 498\u2013507 (2015).","journal-title":"Virology"},{"key":"495_CR111","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41594-019-0334-7","volume":"26","author":"Y-J Park","year":"2019","unstructured":"Park, Y.-J. et al. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Nat. Struct. Mol. Biol. 26, 1151\u20131157 (2019).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"495_CR112","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"495_CR113","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221\u2013224 (2020).","journal-title":"Nature"},{"key":"495_CR114","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abd4251","volume":"369","author":"Y Cai","year":"2020","unstructured":"Cai, Y. et al. Distinct conformational states of SARS-CoV-2 spike protein. Science 369, 1586\u20131592 (2020).","journal-title":"Science"},{"key":"495_CR115","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jviromet.2005.03.021","volume":"128","author":"RA Tripp","year":"2005","unstructured":"Tripp, R. A. et al. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J. Virol. Meth. 128, 21\u201328 (2005).","journal-title":"J. Virol. Meth."},{"key":"495_CR116","doi-asserted-by":"publisher","first-page":"234ra259","DOI":"10.1126\/scitranslmed.3008140","volume":"6","author":"L Jiang","year":"2014","unstructured":"Jiang, L. et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med. 6, 234ra259\u2013234ra259 (2014).","journal-title":"Sci. Transl. Med."},{"key":"495_CR117","first-page":"97-xx98","volume":"63","author":"[No authors listed]","year":"2021","unstructured":"An EUA for sotrovimab for treatment of COVID-19. Med. Lett. Drugs Ther. 63, 97-xx98 (2021).","journal-title":"Med. Lett. Drugs Ther."},{"key":"495_CR118","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1126\/science.abe2402","volume":"370","author":"A Baum","year":"2020","unstructured":"Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110\u20131115 (2020).","journal-title":"Science"},{"key":"495_CR119","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014\u20131018 (2020).","journal-title":"Science"},{"key":"495_CR120","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"495_CR121","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s40265-021-01620-z","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks, E. D. Casirivimab\/Imdevimab: first approval. Drugs 81, 2047\u20132055 (2021).","journal-title":"Drugs"},{"key":"495_CR122","doi-asserted-by":"publisher","unstructured":"Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abf1906 (2021).","DOI":"10.1126\/scitranslmed.abf1906"},{"key":"495_CR123","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"495_CR124","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","volume":"385","author":"M Dougan","year":"2021","unstructured":"Dougan, M. et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N. Engl. J. Med. 385, 1382\u20131392 (2021).","journal-title":"N. Engl. J. Med."},{"key":"495_CR125","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.2021.0202","volume":"325","author":"RL Gottlieb","year":"2021","unstructured":"Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632\u2013644 (2021).","journal-title":"JAMA"},{"key":"495_CR126","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41564-021-00972-2","volume":"6","author":"J Dong","year":"2021","unstructured":"Dong, J. et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol. 6, 1233\u20131244 (2021).","journal-title":"Nat. Microbiol."},{"key":"495_CR127","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"495_CR128","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jama.2021.24931","volume":"327","author":"[No authors listed]","year":"2022","unstructured":"Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. JAMA 327, 384\u2013385 (2022).","journal-title":"JAMA"},{"key":"495_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25997-3","volume":"12","author":"T Li","year":"2021","unstructured":"Li, T. et al. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nat. Commun. 12, 5652 (2021).","journal-title":"Nat. Commun."},{"key":"495_CR130","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2021.06.016","volume":"566","author":"D-K Ryu","year":"2021","unstructured":"Ryu, D.-K. et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem. Biophys. Res. Commun. 566, 135\u2013140 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"495_CR131","doi-asserted-by":"publisher","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).","journal-title":"Cell Rep."},{"key":"495_CR132","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 185, 447\u2013456.e11 (2022).","journal-title":"Cell"},{"key":"495_CR133","doi-asserted-by":"publisher","unstructured":"Fenwick, C. et al. SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique spike binding properties. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.03.18.484873 (2022).","DOI":"10.1101\/2022.03.18.484873"},{"key":"495_CR134","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2020.09.035","volume":"183","author":"S Du","year":"2020","unstructured":"Du, S. et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell 183, 1013\u20131023.e13 (2020).","journal-title":"Cell"},{"key":"495_CR135","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1126\/science.abe3354","volume":"370","author":"MA Tortorici","year":"2020","unstructured":"Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950\u2013957 (2020).","journal-title":"Science"},{"key":"495_CR136","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"495_CR137","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"495_CR138","doi-asserted-by":"publisher","first-page":"109814","DOI":"10.1016\/j.celrep.2021.109814","volume":"37","author":"C Fenwick","year":"2021","unstructured":"Fenwick, C. et al. A highly potent antibody effective against SARS-CoV-2 variants of concern. Cell Rep. 37, 109814 (2021).","journal-title":"Cell Rep."},{"key":"495_CR139","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","volume":"33","author":"NC Wu","year":"2020","unstructured":"Wu, N. C. et al. An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. Cell Rep. 33, 108274 (2020).","journal-title":"Cell Rep."},{"key":"495_CR140","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450\u2013456 (2020).","journal-title":"Nature"},{"key":"495_CR141","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","volume":"183","author":"J Kreye","year":"2020","unstructured":"Kreye, J. et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell 183, 1058\u20131069.e19 (2020).","journal-title":"Cell"},{"key":"495_CR142","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"495_CR143","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","volume":"9","author":"X Tian","year":"2020","unstructured":"Tian, X. et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 9, 382\u2013385 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"495_CR144","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","volume":"27","author":"D Zhou","year":"2020","unstructured":"Zhou, D. et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat. Struct. Mol. Biol. 27, 950\u2013958 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"495_CR145","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"495_CR146","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.chom.2021.03.005","volume":"29","author":"G Cerutti","year":"2021","unstructured":"Cerutti, G. et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 29, 819\u2013833.e7 (2021).","journal-title":"Cell Host Microbe"},{"key":"495_CR147","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","volume":"184","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332\u20132347.e16 (2021).","journal-title":"Cell"},{"key":"495_CR148","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","volume":"184","author":"N Suryadevara","year":"2021","unstructured":"Suryadevara, N. et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 184, 2316\u20132331.e15 (2021).","journal-title":"Cell"},{"key":"495_CR149","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science 369, 650\u2013655 (2020).","journal-title":"Science"},{"key":"495_CR150","doi-asserted-by":"publisher","unstructured":"Shrock, E. et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science https:\/\/doi.org\/10.1126\/science.abd4250 (2020).","DOI":"10.1126\/science.abd4250"},{"key":"495_CR151","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.abj3321","volume":"373","author":"D Pinto","year":"2021","unstructured":"Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109\u20131116 (2021).","journal-title":"Science"},{"key":"495_CR152","doi-asserted-by":"publisher","unstructured":"O\u2019Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent COVID-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2109682 (2021).","DOI":"10.1056\/NEJMoa2109682"},{"key":"495_CR153","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","volume":"584","author":"AM Arvin","year":"2020","unstructured":"Arvin, A. M. et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584, 353\u2013363 (2020).","journal-title":"Nature"},{"key":"495_CR154","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","volume":"17","author":"MB Battles","year":"2019","unstructured":"Battles, M. B. & McLellan, J. S. Respiratory syncytial virus entry and how to block it. Nat. Rev. Microbiol. 17, 233\u2013245 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"495_CR155","first-page":"543","volume":"140","author":"WP Glezen","year":"1986","unstructured":"Glezen, W. P., Taber, L. H., Frank, A. L. & Kasel, J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140, 543\u2013546 (1986).","journal-title":"Am. J. Dis. Child."},{"key":"495_CR156","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","volume":"163","author":"CB Hall","year":"1991","unstructured":"Hall, C. B., Walsh, E. E., Long, C. E. & Schnabel, K. C. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693\u2013698 (1991).","journal-title":"J. Infect. Dis."},{"key":"495_CR157","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics 99, 645\u2013650 (1997).","DOI":"10.1542\/peds.99.4.645"},{"key":"495_CR158","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJM199311183292102","volume":"329","author":"JR Groothuis","year":"1993","unstructured":"Groothuis, J. R. et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med. 329, 1524\u20131530 (1993).","journal-title":"N. Engl. J. Med."},{"key":"495_CR159","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"TI-RS Group","year":"1998","unstructured":"Group, T. I.-R. S. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531\u2013537 (1998).","journal-title":"Pediatrics"},{"key":"495_CR160","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1073\/pnas.1115941109","volume":"109","author":"M Magro","year":"2012","unstructured":"Magro, M. et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl Acad. Sci. USA 109, 3089\u20133094 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR161","doi-asserted-by":"publisher","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","volume":"7","author":"JO Ngwuta","year":"2015","unstructured":"Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).","journal-title":"Sci. Transl. Med."},{"key":"495_CR162","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.1128\/JVI.02699-09","volume":"84","author":"K Huang","year":"2010","unstructured":"Huang, K., Incognito, L., Cheng, X., Ulbrandt, N. D. & Wu, H. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J. Virol. 84, 8132\u20138140 (2010).","journal-title":"J. Virol."},{"key":"495_CR163","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nsmb.1723","volume":"17","author":"JS McLellan","year":"2010","unstructured":"McLellan, J. S. et al. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat. Struct. Mol. Biol. 17, 248\u2013250 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"495_CR164","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1542\/peds.2008-1036","volume":"125","author":"X Carbonell-Estrany","year":"2010","unstructured":"Carbonell-Estrany, X. et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125, e35\u2013e51 (2010).","journal-title":"Pediatrics"},{"key":"495_CR165","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nm.2071","volume":"16","author":"MJ Kwakkenbos","year":"2010","unstructured":"Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123\u2013128 (2010).","journal-title":"Nat. Med."},{"key":"495_CR166","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"495_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01858-w","volume":"8","author":"D Tian","year":"2017","unstructured":"Tian, D. et al. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat. Commun. 8, 1877 (2017).","journal-title":"Nat. Commun."},{"key":"495_CR168","doi-asserted-by":"publisher","unstructured":"Sivapalasingam, S. et al. Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: a new human monoclonal RSV-F antibody for RSV prevention. Open Forum Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofv133.628 (2015).","DOI":"10.1093\/ofid\/ofv133.628"},{"key":"495_CR169","doi-asserted-by":"publisher","unstructured":"Sim\u00f5es, E. A. F. et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa951 (2020).","DOI":"10.1093\/cid\/ciaa951"},{"key":"495_CR170","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","volume":"393","author":"D Malvy","year":"2019","unstructured":"Malvy, D., McElroy, A. K., de Clerck, H., G\u00fcnther, S. & van Griensven, J. Ebola virus disease. Lancet 393, 936\u2013948 (2019).","journal-title":"Lancet"},{"key":"495_CR171","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature07082","volume":"454","author":"JE Lee","year":"2008","unstructured":"Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177\u2013182 (2008).","journal-title":"Nature"},{"key":"495_CR172","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature10380","volume":"477","author":"M C\u00f4t\u00e9","year":"2011","unstructured":"C\u00f4t\u00e9, M. et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344\u2013348 (2011).","journal-title":"Nature"},{"key":"495_CR173","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1128\/JVI.05549-11","volume":"86","author":"D Olal","year":"2012","unstructured":"Olal, D. et al. Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. J. Virol. 86, 2809\u20132816 (2012).","journal-title":"J. Virol."},{"key":"495_CR174","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","volume":"287","author":"JA Wilson","year":"2000","unstructured":"Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664\u20131666 (2000).","journal-title":"Science"},{"key":"495_CR175","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature13777","volume":"514","author":"X Qiu","year":"2014","unstructured":"Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47\u201353 (2014).","journal-title":"Nature"},{"key":"495_CR176","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.aad5224","volume":"351","author":"D Corti","year":"2016","unstructured":"Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339\u20131342 (2016).","journal-title":"Science"},{"key":"495_CR177","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.aad6117","volume":"351","author":"J Misasi","year":"2016","unstructured":"Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343\u20131346 (2016).","journal-title":"Science"},{"key":"495_CR178","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","volume":"218","author":"KE Pascal","year":"2018","unstructured":"Pascal, K. E. et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. J. Infect. Dis. 218, S612\u2013s626 (2018).","journal-title":"J. Infect. Dis."},{"key":"495_CR179","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"495_CR180","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. REGN-EB3: first approval. Drugs 81, 175\u2013178 (2021).","journal-title":"Drugs"},{"key":"495_CR181","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40265-021-01483-4","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee, A. Ansuvimab: first approval. Drugs 81, 595\u2013598 (2021).","journal-title":"Drugs"},{"key":"495_CR182","doi-asserted-by":"publisher","unstructured":"Griffiths, P. & Reeves, M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat. Rev. Microbiol. https:\/\/doi.org\/10.1038\/s41579-021-00582-z (2021).","DOI":"10.1038\/s41579-021-00582-z"},{"key":"495_CR183","first-page":"16","volume":"35","author":"MR Schleiss","year":"2018","unstructured":"Schleiss, M. R. Congenital cytomegalovirus: impact on child health. Contemp. Pediatr. 35, 16\u201324 (2018).","journal-title":"Contemp. Pediatr."},{"key":"495_CR184","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1073\/pnas.1424818112","volume":"112","author":"C Ciferri","year":"2015","unstructured":"Ciferri, C. et al. Structural and biochemical studies of HCMV gH\/gL\/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc. Natl Acad. Sci. USA 112, 1767\u20131772 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR185","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3389\/fmicb.2019.01005","volume":"10","author":"M Foglierini","year":"2019","unstructured":"Foglierini, M., Marcandalli, J. & Perez, L. HCMV envelope glycoprotein diversity demystified. Front. Microbiol. 10, 1005 (2019).","journal-title":"Front. Microbiol."},{"key":"495_CR186","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nmicrobiol.2016.82","volume":"1","author":"A Kabanova","year":"2016","unstructured":"Kabanova, A. et al. Platelet-derived growth factor-\u03b1 receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. Nat. Microbiol. 1, 16082 (2016).","journal-title":"Nat. Microbiol."},{"key":"495_CR187","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2021.01.036","volume":"184","author":"M Kschonsak","year":"2021","unstructured":"Kschonsak, M. et al. Structures of HCMV Trimer reveal the basis for receptor recognition and cell entry. Cell 184, 1232\u20131244.e16 (2021).","journal-title":"Cell"},{"key":"495_CR188","doi-asserted-by":"publisher","unstructured":"Martinez-Martin, N. et al. An unbiased screen for human cytomegalovirus identifies Neuropilin-2 as a central viral receptor. Cell https:\/\/doi.org\/10.1016\/j.cell.2018.06.028 (2018).","DOI":"10.1016\/j.cell.2018.06.028"},{"key":"495_CR189","doi-asserted-by":"publisher","first-page":"eabm2536","DOI":"10.1126\/sciadv.abm2536","volume":"8","author":"M Kschonsak","year":"2022","unstructured":"Kschonsak, M. et al. Structural basis for HCMV Pentamer receptor recognition and antibody neutralization. Sci. Adv. 8, eabm2536 (2022).","journal-title":"Sci. Adv."},{"key":"495_CR190","doi-asserted-by":"publisher","first-page":"eabm2546","DOI":"10.1126\/sciadv.abm2546","volume":"8","author":"D Wrapp","year":"2022","unstructured":"Wrapp, D. et al. Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies. Sci. Adv. 8, eabm2546 (2022).","journal-title":"Sci. Adv."},{"key":"495_CR191","doi-asserted-by":"publisher","first-page":"e00332","DOI":"10.1128\/mBio.00332-13","volume":"4","author":"PT Wille","year":"2013","unstructured":"Wille, P. T., Wisner, T. W., Ryckman, B. & Johnson, D. C. Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein. MBio 4, e00332\u201300313 (2013).","journal-title":"MBio"},{"key":"495_CR192","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005227","volume":"11","author":"HG Burke","year":"2015","unstructured":"Burke, H. G. & Heldwein, E. E. Crystal structure of the human cytomegalovirus glycoprotein B. PLoS Pathog. 11, e1005227 (2015).","journal-title":"PLoS Pathog."},{"key":"495_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9176","volume":"6","author":"S Chandramouli","year":"2015","unstructured":"Chandramouli, S. et al. Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody. Nat. Commun. 6, 8176 (2015).","journal-title":"Nat. Commun."},{"key":"495_CR194","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009169","volume":"16","author":"M Perotti","year":"2020","unstructured":"Perotti, M., Marcandalli, J., Demurtas, D., Sallusto, F. & Perez, L. Rationally designed human cytomegalovirus gB nanoparticle vaccine with improved immunogenicity. PLoS Pathog. 16, e1009169 (2020).","journal-title":"PLoS Pathog."},{"key":"495_CR195","doi-asserted-by":"publisher","first-page":"104734","DOI":"10.1016\/j.jcv.2021.104734","volume":"135","author":"E Gabanti","year":"2021","unstructured":"Gabanti, E. et al. Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. J. Clin. Virol. 135, 104734 (2021).","journal-title":"J. Clin. Virol."},{"key":"495_CR196","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jcv.2007.12.001","volume":"41","author":"F Baldanti","year":"2008","unstructured":"Baldanti, F., Lilleri, D. & Gerna, G. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41, 237\u2013241 (2008).","journal-title":"J. Clin. Virol."},{"key":"495_CR197","doi-asserted-by":"publisher","first-page":"8209","DOI":"10.1073\/pnas.1404653111","volume":"111","author":"AE Fouts","year":"2014","unstructured":"Fouts, A. E. et al. Mechanism for neutralizing activity by the anti-CMV gH\/gL monoclonal antibody MSL-109. Proc. Natl Acad. Sci. USA 111, 8209\u20138214 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR198","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/00002030-200204120-00007","volume":"16","author":"DA Jabs","year":"2002","unstructured":"Jabs, D. A. et al. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: monoclonal antibody cytomegalovirus retinitis trial. AIDS 16, 877\u2013887 (2002).","journal-title":"AIDS"},{"key":"495_CR199","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1128\/AAC.00523-15","volume":"59","author":"JH Ishida","year":"2015","unstructured":"Ishida, J. H. et al. Phase 1 randomized, double-blind, placebo-controlled study of RG7667, an anticytomegalovirus combination monoclonal antibody therapy, in healthy adults. Antimicrob. Agents Chemother. 59, 4919\u20134929 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"495_CR200","doi-asserted-by":"publisher","unstructured":"Ishida, J. H. et al. Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01794-16 (2017).","DOI":"10.1128\/aac.01794-16"},{"key":"495_CR201","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1128\/AAC.00382-16","volume":"60","author":"HD Patel","year":"2016","unstructured":"Patel, H. D. et al. In vitro characterization of human cytomegalovirus-targeting therapeutic monoclonal antibodies LJP538 and LJP539. Antimicrob. Agents Chemother. 60, 4961\u20134971 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"495_CR202","doi-asserted-by":"publisher","unstructured":"Maertens, J. et al. Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02467-19 (2020).","DOI":"10.1128\/aac.02467-19"},{"key":"495_CR203","doi-asserted-by":"publisher","unstructured":"Nelson, C. S. et al. Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.94002 (2017).","DOI":"10.1172\/jci.insight.94002"},{"key":"495_CR204","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","volume":"370","author":"MG Revello","year":"2014","unstructured":"Revello, M. G. et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N. Engl. J. Med. 370, 1316\u20131326 (2014).","journal-title":"N. Engl. J. Med."},{"key":"495_CR205","first-page":"2544","volume":"370","author":"A Spinillo","year":"2014","unstructured":"Spinillo, A. & Gerna, G. Hyperimmune globulin to prevent congenital CMV infection. N. Engl. J. Med. 370, 2544\u20132545 (2014).","journal-title":"N. Engl. J. Med."},{"key":"495_CR206","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","volume":"25","author":"S Yamayoshi","year":"2019","unstructured":"Yamayoshi, S. & Kawaoka, Y. Current and future influenza vaccines. Nat. Med. 25, 212\u2013220 (2019).","journal-title":"Nat. Med."},{"key":"495_CR207","doi-asserted-by":"publisher","unstructured":"Jones, J. E. et al. Parallel evolution between genomic segments of seasonal human influenza viruses reveals RNA-RNA relationships. eLife https:\/\/doi.org\/10.7554\/eLife.66525 (2021).","DOI":"10.7554\/eLife.66525"},{"key":"495_CR208","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/infdis\/jiy696","volume":"219","author":"SJ Zost","year":"2019","unstructured":"Zost, S. J., Wu, N. C., Hensley, S. E. & Wilson, I. A. Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens. J. Infect. Dis. 219, S38\u2013S45 (2019).","journal-title":"J. Infect. Dis."},{"key":"495_CR209","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1073\/pnas.1916585116","volume":"117","author":"RK Virk","year":"2020","unstructured":"Virk, R. K. et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc. Natl Acad. Sci. USA 117, 619\u2013628 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR210","doi-asserted-by":"publisher","first-page":"18137","DOI":"10.1073\/pnas.0909696106","volume":"106","author":"C-C Wang","year":"2009","unstructured":"Wang, C.-C. et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl Acad. Sci. USA 106, 18137\u201318142 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR211","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41594-018-0025-9","volume":"25","author":"NC Wu","year":"2018","unstructured":"Wu, N. C. & Wilson, I. A. Structural insights into the design of novel anti-influenza therapies. Nat. Struct. Mol. Biol. 25, 115\u2013121 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"495_CR212","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"495_CR213","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.chom.2015.02.005","volume":"17","author":"N Tzarum","year":"2015","unstructured":"Tzarum, N. et al. Structure and receptor binding of the hemagglutinin from a human H6N1 influenza virus. Cell Host Microbe 17, 369\u2013376 (2015).","journal-title":"Cell Host Microbe"},{"key":"495_CR214","doi-asserted-by":"publisher","first-page":"108088","DOI":"10.1016\/j.celrep.2020.108088","volume":"32","author":"CS Cheung","year":"2020","unstructured":"Cheung, C. S. et al. Identification and structure of a multidonor class of head-directed influenza-neutralizing antibodies reveal the mechanism for its recurrent elicitation. Cell Rep. 32, 108088 (2020).","journal-title":"Cell Rep."},{"key":"495_CR215","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature11414","volume":"489","author":"DC Ekiert","year":"2012","unstructured":"Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526\u2013532 (2012).","journal-title":"Nature"},{"key":"495_CR216","doi-asserted-by":"publisher","first-page":"17040","DOI":"10.1073\/pnas.1212371109","volume":"109","author":"PS Lee","year":"2012","unstructured":"Lee, P. S. et al. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc. Natl Acad. Sci. USA 109, 17040\u201317045 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR217","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4614","volume":"5","author":"PS Lee","year":"2014","unstructured":"Lee, P. S. et al. Receptor mimicry by antibody F045\u2013092 facilitates universal binding to the H3 subtype of influenza virus. Nat. Commun. 5, 3614 (2014).","journal-title":"Nat. Commun."},{"key":"495_CR218","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.chom.2019.04.003","volume":"25","author":"G Bajic","year":"2019","unstructured":"Bajic, G. et al. Influenza antigen engineering focuses immune responses to a subdominant but broadly protective viral epitope. Cell Host Microbe 25, 827\u2013835.e6 (2019).","journal-title":"Cell Host Microbe"},{"key":"495_CR219","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","volume":"177","author":"S Bangaru","year":"2019","unstructured":"Bangaru, S. et al. A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell 177, 1136\u20131152.e18 (2019).","journal-title":"Cell"},{"key":"495_CR220","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065\u20131070 (2015).","journal-title":"Nat. Med."},{"key":"495_CR221","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","volume":"19","author":"CJ Wei","year":"2020","unstructured":"Wei, C. J. et al. Next-generation influenza vaccines: opportunities and challenges. Nat. Rev. Drug Discov. 19, 239\u2013252 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"495_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20879-6","volume":"12","author":"WD Harshbarger","year":"2021","unstructured":"Harshbarger, W. D. et al. Unique structural solution from a V(H)3-30 antibody targeting the hemagglutinin stem of influenza A viruses. Nat. Commun. 12, 559 (2021).","journal-title":"Nat. Commun."},{"key":"495_CR223","doi-asserted-by":"publisher","first-page":"11931","DOI":"10.1073\/pnas.1609316113","volume":"113","author":"W He","year":"2016","unstructured":"He, W. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl Acad. Sci. USA 113, 11931\u201311936 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR224","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nsmb.1566","volume":"16","author":"J Sui","year":"2009","unstructured":"Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265\u2013273 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"495_CR225","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003942","volume":"3","author":"M Throsby","year":"2008","unstructured":"Throsby, M. et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942 (2008).","journal-title":"PLoS ONE"},{"key":"495_CR226","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1126\/science.1204839","volume":"333","author":"DC Ekiert","year":"2011","unstructured":"Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843\u2013850 (2011).","journal-title":"Science"},{"key":"495_CR227","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1073\/pnas.1319058110","volume":"111","author":"RH Friesen","year":"2014","unstructured":"Friesen, R. H. et al. A common solution to group 2 influenza virus neutralization. Proc. Natl Acad. Sci. USA 111, 445\u2013450 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR228","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1073\/pnas.1114927109","volume":"109","author":"E Giang","year":"2012","unstructured":"Giang, E. et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl Acad. Sci. USA 109, 6205\u20136210 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR229","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","volume":"333","author":"D Corti","year":"2011","unstructured":"Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850\u2013856 (2011).","journal-title":"Science"},{"key":"495_CR230","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"495_CR231","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.chom.2013.06.004","volume":"14","author":"G Nakamura","year":"2013","unstructured":"Nakamura, G. et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14, 93\u2013103 (2013).","journal-title":"Cell Host Microbe"},{"key":"495_CR232","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","volume":"166","author":"NL Kallewaard","year":"2016","unstructured":"Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166, 596\u2013608 (2016).","journal-title":"Cell"},{"key":"495_CR233","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","volume":"349","author":"A Impagliazzo","year":"2015","unstructured":"Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301\u20131306 (2015).","journal-title":"Science"},{"key":"495_CR234","doi-asserted-by":"publisher","unstructured":"Ali, S. O. et al. Evaluation of MEDI8852, an anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00694-18 (2018).","DOI":"10.1128\/aac.00694-18"},{"key":"495_CR235","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1377\/hlthaff.24.3.611","volume":"24","author":"AM Stern","year":"2005","unstructured":"Stern, A. M. & Markel, H. The history of vaccines and immunization: familiar patterns, new challenges. Health Aff. 24, 611\u2013621 (2005).","journal-title":"Health Aff."},{"key":"495_CR236","doi-asserted-by":"publisher","unstructured":"Burton, D. R. What are the most powerful immunogen design vaccine strategies? Reverse vaccinology 2.0 shows great promise. Cold Spring Harb. Perspect. Biol. https:\/\/doi.org\/10.1101\/cshperspect.a030262 (2017).","DOI":"10.1101\/cshperspect.a030262"},{"key":"495_CR237","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"495_CR238","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.3390\/ijms160613106","volume":"16","author":"E Malito","year":"2015","unstructured":"Malito, E., Carfi, A. & Bottomley, M. J. Protein crystallography in vaccine research and development. Int. J. Mol. Sci. 16, 13106\u201313140 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"495_CR239","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.coi.2016.06.001","volume":"41","author":"A Lanzavecchia","year":"2016","unstructured":"Lanzavecchia, A., Fr\u00fchwirth, A., Perez, L. & Corti, D. Antibody-guided vaccine design: identification of protective epitopes. Curr. Opin. Immunol. 41, 62\u201367 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"495_CR240","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nri3285","volume":"12","author":"PC Wilson","year":"2012","unstructured":"Wilson, P. C. & Andrews, S. F. Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol. 12, 709\u2013719 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"495_CR241","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.molmed.2003.09.001","volume":"9","author":"R Pantophlet","year":"2003","unstructured":"Pantophlet, R. & Burton, D. R. Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Trends Mol. Med. 9, 468\u2013473 (2003).","journal-title":"Trends Mol. Med."},{"key":"495_CR242","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.sbi.2018.06.002","volume":"51","author":"F Sesterhenn","year":"2018","unstructured":"Sesterhenn, F., Bonet, J. & Correia, B. E. Structure-based immunogen design-leading the way to the new age of precision vaccines. Curr. Opin. Struct. Biol. 51, 163\u2013169 (2018).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"495_CR243","doi-asserted-by":"publisher","unstructured":"Gilman, M. S. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aaj1879 (2016).","DOI":"10.1126\/sciimmunol.aaj1879"},{"key":"495_CR244","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159709","volume":"11","author":"JC Boyington","year":"2016","unstructured":"Boyington, J. C. et al. Structure-based design of head-only fusion glycoprotein immunogens for respiratory syncytial virus. PLOS ONE 11, e0159709 (2016).","journal-title":"PLOS ONE"},{"key":"495_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9143","volume":"6","author":"A Krarup","year":"2015","unstructured":"Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).","journal-title":"Nat. Commun."},{"key":"495_CR246","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nsmb.3267","volume":"23","author":"MG Joyce","year":"2016","unstructured":"Joyce, M. G. et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat. Struct. Mol. Biol. 23, 811\u2013820 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"495_CR247","doi-asserted-by":"publisher","first-page":"156241","DOI":"10.1155\/2015\/156241","volume":"2015","author":"L Liljeroos","year":"2015","unstructured":"Liljeroos, L., Malito, E., Ferlenghi, I. & Bottomley, M. J. Structural and computational biology in the design of immunogenic vaccine antigens. J. Immunol. Res. 2015, 156241 (2015).","journal-title":"J. Immunol. Res."},{"key":"495_CR248","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.str.2010.06.010","volume":"18","author":"BE Correia","year":"2010","unstructured":"Correia, B. E. et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18, 1116\u20131126 (2010).","journal-title":"Structure"},{"key":"495_CR249","doi-asserted-by":"publisher","first-page":"17880","DOI":"10.1073\/pnas.1004728107","volume":"107","author":"G Ofek","year":"2010","unstructured":"Ofek, G. et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl Acad. Sci. USA 107, 17880\u201317887 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR250","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016074","volume":"6","author":"J Guenaga","year":"2011","unstructured":"Guenaga, J. et al. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 6, e16074 (2011).","journal-title":"PLoS ONE"},{"key":"495_CR251","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jmb.2011.10.003","volume":"415","author":"ML Azoitei","year":"2012","unstructured":"Azoitei, M. L. et al. Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J. Mol. Biol. 415, 175\u2013192 (2012).","journal-title":"J. Mol. Biol."},{"key":"495_CR252","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41580-019-0163-x","volume":"20","author":"B Kuhlman","year":"2019","unstructured":"Kuhlman, B. & Bradley, P. Advances in protein structure prediction and design. Nat. Rev. Mol. Cell Biol. 20, 681\u2013697 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"495_CR253","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jmb.2011.04.044","volume":"409","author":"JS McLellan","year":"2011","unstructured":"McLellan, J. S. et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J. Mol. Biol. 409, 853\u2013866 (2011).","journal-title":"J. Mol. Biol."},{"key":"495_CR254","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature12966","volume":"507","author":"BE Correia","year":"2014","unstructured":"Correia, B. E. et al. Proof of principle for epitope-focused vaccine design. Nature 507, 201\u2013206 (2014).","journal-title":"Nature"},{"key":"495_CR255","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000164","volume":"17","author":"F Sesterhenn","year":"2019","unstructured":"Sesterhenn, F. et al. Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. PLoS Biol. 17, e3000164 (2019).","journal-title":"PLoS Biol."},{"key":"495_CR256","doi-asserted-by":"publisher","unstructured":"Sesterhenn, F. et al. De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science https:\/\/doi.org\/10.1126\/science.aay5051 (2020).","DOI":"10.1126\/science.aay5051"},{"key":"495_CR257","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1209368","volume":"334","author":"ML Azoitei","year":"2011","unstructured":"Azoitei, M. L. et al. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334, 373\u2013376 (2011).","journal-title":"Science"},{"key":"495_CR258","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1016\/j.molimm.2007.10.016","volume":"45","author":"ND Rubinstein","year":"2008","unstructured":"Rubinstein, N. D. et al. Computational characterization of B-cell epitopes. Mol. Immunol. 45, 3477\u20133489 (2008).","journal-title":"Mol. Immunol."},{"key":"495_CR259","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0022-2836(92)90636-X","volume":"226","author":"L Jin","year":"1992","unstructured":"Jin, L., Fendly, B. M. & Wells, J. A. High resolution functional analysis of antibody-antigen interactions. J. Mol. Biol. 226, 851\u2013865 (1992).","journal-title":"J. Mol. Biol."},{"key":"495_CR260","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","volume":"176","author":"J Marcandalli","year":"2019","unstructured":"Marcandalli, J. et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell 176, 1420\u20131431.e17 (2019).","journal-title":"Cell"},{"key":"495_CR261","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.cell.2021.01.035","volume":"184","author":"PJM Brouwer","year":"2021","unstructured":"Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188\u20131200.e19 (2021).","journal-title":"Cell"},{"key":"495_CR262","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","volume":"592","author":"S Boyoglu-Barnum","year":"2021","unstructured":"Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623\u2013628 (2021).","journal-title":"Nature"},{"key":"495_CR263","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1086\/514280","volume":"179","author":"T Maruyama","year":"1999","unstructured":"Maruyama, T. et al. Recombinant human monoclonal antibodies to Ebola virus. J. Infect. Dis. 179, S235\u2013S239 (1999).","journal-title":"J. Infect. Dis."},{"key":"495_CR264","doi-asserted-by":"publisher","first-page":"199ra113","DOI":"10.1126\/scitranslmed.3006608","volume":"5","author":"J Pettitt","year":"2013","unstructured":"Pettitt, J. et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 5, 199ra113\u2013199ra113 (2013).","journal-title":"Sci. Transl. Med."},{"key":"495_CR265","doi-asserted-by":"publisher","first-page":"S528","DOI":"10.1093\/infdis\/jiy333","volume":"218","author":"A Cagigi","year":"2018","unstructured":"Cagigi, A. et al. Vaccine generation of protective ebola antibodies and identification of conserved B-cell signatures. J. Infect. Dis. 218, S528\u2013s536 (2018).","journal-title":"J. Infect. Dis."},{"key":"495_CR266","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","volume":"27","author":"P Rijal","year":"2019","unstructured":"Rijal, P. et al. Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell Rep. 27, 172\u2013186.e7 (2019).","journal-title":"Cell Rep."},{"key":"495_CR267","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22867-w","volume":"12","author":"L He","year":"2021","unstructured":"He, L. et al. Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. Nat. Commun. 12, 2633 (2021).","journal-title":"Nat. Commun."},{"key":"495_CR268","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med."},{"key":"495_CR269","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1073\/pnas.1209591110","volume":"110","author":"A Marzi","year":"2013","unstructured":"Marzi, A. et al. Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110, 1893\u20131898 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR270","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"495_CR271","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/infdis\/jiz071","volume":"220","author":"G Mutua","year":"2019","unstructured":"Mutua, G. et al. Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya. J. Infect. Dis. 220, 57\u201367 (2019).","journal-title":"J. Infect. Dis."},{"key":"495_CR272","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood, J. E. et al. Chimpanzee adenovirus vector Ebola vaccine. N. Engl. J. Med. 376, 928\u2013938 (2017).","journal-title":"N. Engl. J. Med."},{"key":"495_CR273","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature14442","volume":"521","author":"EP Thi","year":"2015","unstructured":"Thi, E. P. et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521, 362\u2013365 (2015).","journal-title":"Nature"},{"key":"495_CR274","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(74)92997-3","volume":"303","author":"S Elek","year":"1974","unstructured":"Elek, S. & Stern, H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 303, 1\u20135 (1974).","journal-title":"Lancet"},{"key":"495_CR275","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1128\/iai.12.3.521-527.1975","volume":"12","author":"SA Plotkin","year":"1975","unstructured":"Plotkin, S. A., Furukawa, T., Zygraich, N. & Huygelen, C. Candidate cytomegalovirus strain for human vaccination. Infect. Immun. 12, 521\u2013527 (1975).","journal-title":"Infect. Immun."},{"key":"495_CR276","first-page":"1176","volume":"58","author":"SA Plotkin","year":"1994","unstructured":"Plotkin, S. A. et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58, 1176\u20131178 (1994).","journal-title":"Transplantation"},{"key":"495_CR277","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1073\/pnas.1800177115","volume":"115","author":"S Nelson Cody","year":"2018","unstructured":"Nelson Cody, S. et al. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc. Natl Acad. Sci. USA 115, 6267\u20136272 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR278","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","volume":"360","author":"RF Pass","year":"2009","unstructured":"Pass, R. F. et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360, 1191\u20131199 (2009).","journal-title":"N. Engl. J. Med."},{"key":"495_CR279","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","volume":"377","author":"PD Griffiths","year":"2011","unstructured":"Griffiths, P. D. et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377, 1256\u20131263 (2011).","journal-title":"Lancet"},{"key":"495_CR280","doi-asserted-by":"publisher","first-page":"eabf3178","DOI":"10.1126\/sciadv.abf3178","volume":"7","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion. Sci. Adv. 7, eabf3178 (2021).","journal-title":"Sci. Adv."},{"key":"495_CR281","doi-asserted-by":"publisher","first-page":"18153","DOI":"10.1073\/pnas.0509201102","volume":"102","author":"D Wang","year":"2005","unstructured":"Wang, D. & Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl Acad. Sci. USA 102, 18153\u201318158 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR282","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/jmv.25225","volume":"90","author":"D Lilleri","year":"2018","unstructured":"Lilleri, D. et al. Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients. J. Med. Virol. 90, 1620\u20131628 (2018).","journal-title":"J. Med. Virol."},{"key":"495_CR283","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1128\/JVI.00137-12","volume":"86","author":"R Hai","year":"2012","unstructured":"Hai, R. et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86, 5774\u20135781 (2012).","journal-title":"J. Virol."},{"key":"495_CR284","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1128\/JVI.00641-13","volume":"87","author":"F Krammer","year":"2013","unstructured":"Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542\u20136550 (2013).","journal-title":"J. Virol."},{"key":"495_CR285","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1128\/JVI.01715-13","volume":"87","author":"I Margine","year":"2013","unstructured":"Margine, I. et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87, 10435\u201310446 (2013).","journal-title":"J. Virol."},{"key":"495_CR286","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1128\/JVI.03004-13","volume":"88","author":"F Krammer","year":"2014","unstructured":"Krammer, F. et al. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 88, 3432\u20133442 (2014).","journal-title":"J. Virol."},{"key":"495_CR287","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1128\/JVI.02481-15","volume":"90","author":"R Nachbagauer","year":"2015","unstructured":"Nachbagauer, R. et al. Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets. J. Virol. 90, 3268\u20133273 (2015).","journal-title":"J. Virol."},{"key":"495_CR288","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"495_CR289","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","volume":"20","author":"M Kanekiyo","year":"2019","unstructured":"Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362\u2013372 (2019).","journal-title":"Nat. Immunol."},{"key":"495_CR290","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1073\/pnas.1308701110","volume":"111","author":"Y Lu","year":"2014","unstructured":"Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl Acad. Sci. USA 111, 125\u2013130 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR291","doi-asserted-by":"publisher","first-page":"13701","DOI":"10.1073\/pnas.1007465107","volume":"107","author":"G Bommakanti","year":"2010","unstructured":"Bommakanti, G. et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl Acad. Sci. USA 107, 13701\u201313706 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR292","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio https:\/\/doi.org\/10.1128\/mBio.02810-18 (2019).","DOI":"10.1128\/mBio.02810-18"},{"key":"495_CR293","doi-asserted-by":"publisher","unstructured":"Darricarr\u00e8re, N. et al. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abe5449 (2021).","DOI":"10.1126\/scitranslmed.abe5449"},{"key":"495_CR294","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41541-018-0063-7","volume":"3","author":"JEM van der Lubbe","year":"2018","unstructured":"van der Lubbe, J. E. M. et al. Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge. NPJ Vaccin. 3, 25 (2018).","journal-title":"NPJ Vaccin."},{"key":"495_CR295","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41591-021-01636-8","volume":"28","author":"SF Andrews","year":"2022","unstructured":"Andrews, S. F. et al. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Nat. Med. 28, 373\u2013382 (2022).","journal-title":"Nat. Med."},{"key":"495_CR296","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","volume":"28","author":"KV Houser","year":"2022","unstructured":"Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383\u2013391 (2022).","journal-title":"Nat. Med."},{"key":"495_CR297","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1073\/pnas.1819197116","volume":"116","author":"YC Tseng","year":"2019","unstructured":"Tseng, Y. C. et al. Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections. Proc. Natl Acad. Sci. USA 116, 4200\u20134205 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR298","doi-asserted-by":"publisher","first-page":"9947","DOI":"10.1073\/pnas.1822062116","volume":"116","author":"PA Weidenbacher","year":"2019","unstructured":"Weidenbacher, P. A. & Kim, P. S. Protect, modify, deprotect (PMD): a strategy for creating vaccines to elicit antibodies targeting a specific epitope. Proc. Natl Acad. Sci. USA 116, 9947\u20139952 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR299","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1128\/JVI.02608-13","volume":"88","author":"D Eggink","year":"2014","unstructured":"Eggink, D., Goff, P. H. & Palese, P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 88, 699\u2013704 (2014).","journal-title":"J. Virol."},{"key":"495_CR300","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature17200","volume":"531","author":"RN Kirchdoerfer","year":"2016","unstructured":"Kirchdoerfer, R. N. et al. Pre-fusion structure of a human coronavirus spike protein. Nature 531, 118\u2013121 (2016).","journal-title":"Nature"},{"key":"495_CR301","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348\u2013E7357 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"495_CR302","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature16988","volume":"531","author":"AC Walls","year":"2016","unstructured":"Walls, A. C. et al. Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature 531, 114\u2013117 (2016).","journal-title":"Nature"},{"key":"495_CR303","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","volume":"21","author":"M Sadarangani","year":"2021","unstructured":"Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21, 475\u2013484 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"495_CR304","first-page":"e02648","volume":"12","author":"F Amanat","year":"2021","unstructured":"Amanat, F. et al. Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model. mBio 12, e02648\u201302620 (2021).","journal-title":"mBio"},{"key":"495_CR305","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"495_CR306","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292.e286 (2020).","journal-title":"Cell"},{"key":"495_CR307","doi-asserted-by":"publisher","unstructured":"Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz2686 (2019).","DOI":"10.1126\/scitranslmed.aaz2686"},{"key":"495_CR308","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","volume":"19","author":"D Sok","year":"2018","unstructured":"Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179\u20131188 (2018).","journal-title":"Nat. Immunol."},{"key":"495_CR309","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","volume":"25","author":"M Caskey","year":"2019","unstructured":"Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 25, 547\u2013553 (2019).","journal-title":"Nat. Med."},{"key":"495_CR310","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd.2016.173","volume":"15","author":"G Ferrari","year":"2016","unstructured":"Ferrari, G. et al. Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. Nat. Rev. Drug Discov. 15, 823\u2013834 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"495_CR311","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25797","volume":"24","author":"R Derking","year":"2021","unstructured":"Derking, R. & Sanders, R. W. Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. J. Int. AIDS Soc. 24, e25797 (2021).","journal-title":"J. Int. AIDS Soc."},{"key":"495_CR312","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/COH.0000000000000548","volume":"14","author":"AT McGuire","year":"2019","unstructured":"McGuire, A. T. Targeting broadly neutralizing antibody precursors: a na\u00efve approach to vaccine design. Curr. Opin. HIV AIDS 14, 294\u2013301 (2019).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"495_CR313","doi-asserted-by":"publisher","first-page":"E95","DOI":"10.1016\/S2666-5247(21)00042-2","volume":"2","author":"P Venkatesen","year":"2021","unstructured":"Venkatesen, P. Preliminary phase 1 results from an HIV vaccine candidate trial. Lancet Microbe 2, E95 (2021).","journal-title":"Lancet Microbe"},{"key":"495_CR314","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1126\/science.aad9195","volume":"351","author":"JG Jardine","year":"2016","unstructured":"Jardine, J. G. et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351, 1458\u20131463 (2016).","journal-title":"Science"},{"key":"495_CR315","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1126\/science.aah3945","volume":"353","author":"D Sok","year":"2016","unstructured":"Sok, D. et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 353, 1557\u20131560 (2016).","journal-title":"Science"},{"key":"495_CR316","doi-asserted-by":"publisher","unstructured":"Crowe, J. E. Jr Human antibodies for viral infections. Annu. Rev. Immunol. https:\/\/doi.org\/10.1146\/annurev-immunol-042718-041309 (2022).","DOI":"10.1146\/annurev-immunol-042718-041309"},{"key":"495_CR317","doi-asserted-by":"publisher","first-page":"139.e135","DOI":"10.1016\/j.cmi.2021.09.008","volume":"28","author":"C Vellas","year":"2022","unstructured":"Vellas, C. et al. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies. Clin. Microbiol. Infect. 28, 139.e135\u2013139.e8 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"495_CR318","doi-asserted-by":"publisher","unstructured":"Rockett, R. et al. Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2120219 (2022).","DOI":"10.1056\/NEJMc2120219"},{"key":"495_CR319","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi, B. et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N. Engl. J. Med. 383, 2291\u20132293 (2020).","journal-title":"N. Engl. J. Med."},{"key":"495_CR320","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.sbi.2020.11.008","volume":"67","author":"S Vajda","year":"2021","unstructured":"Vajda, S., Porter, K. A. & Kozakov, D. Progress toward improved understanding of antibody maturation. Curr. Opin. Struct. Biol. 67, 226\u2013231 (2021).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"495_CR321","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","volume":"38","author":"DN Nguyen","year":"2020","unstructured":"Nguyen, D. N. et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat. Biotechnol. 38, 44\u201349 (2020).","journal-title":"Nat. Biotechnol."},{"key":"495_CR322","doi-asserted-by":"publisher","unstructured":"Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01792-5 (2022).","DOI":"10.1038\/s41591-022-01792-5"},{"key":"495_CR323","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681 (2022).","journal-title":"Nature"},{"key":"495_CR324","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"495_CR325","unstructured":"ACTIV-3\/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. 22, 622\u2013635 (2022)."},{"key":"495_CR326","doi-asserted-by":"publisher","unstructured":"VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01678-y (2022).","DOI":"10.1038\/s41591-021-01678-y"},{"key":"495_CR327","doi-asserted-by":"publisher","unstructured":"Self, W. H. et al. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(21)00751-9 (2021).","DOI":"10.1016\/S1473-3099(21)00751-9"},{"key":"495_CR328","doi-asserted-by":"publisher","first-page":"eabg6916","DOI":"10.1126\/sciimmunol.abg6916","volume":"6","author":"M Sakharkar","year":"2021","unstructured":"Sakharkar, M. et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci. Immunol. 6, eabg6916 (2021).","journal-title":"Sci. Immunol."},{"key":"495_CR329","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/molecules16010412","volume":"16","author":"T Schirrmann","year":"2011","unstructured":"Schirrmann, T., Meyer, T., Sch\u00fctte, M., Frenzel, A. & Hust, M. Phage display for the generation of antibodies for proteome research, diagnostics and therapy. Molecules 16, 412\u2013426 (2011).","journal-title":"Molecules"},{"key":"495_CR330","doi-asserted-by":"publisher","unstructured":"Zurawski, D. V. & McLendon, M. K. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics https:\/\/doi.org\/10.3390\/antibiotics9040155 (2020).","DOI":"10.3390\/antibiotics9040155"},{"key":"495_CR331","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","volume":"73","author":"N Mohamed","year":"2005","unstructured":"Mohamed, N. et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73, 795\u2013802 (2005).","journal-title":"Infect. Immun."},{"key":"495_CR332","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa1602615","volume":"376","author":"MH Wilcox","year":"2017","unstructured":"Wilcox, M. H. et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N. Engl. J. Med. 376, 305\u2013317 (2017).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-022-00495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-022-00495-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-022-00495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T15:51:35Z","timestamp":1675871495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-022-00495-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":332,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1038\/s41573-022-00495-3","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"16 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}